Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jul 17, 2026
Interactive Brokers (IBKR): Can It Hit $100 After +46% Gains?

Interactive Brokers (IBKR): Can It Hit $100 After +46% Gains?

Key Takeaways

  • Price target: $100 per share — a major psychological milestone that Interactive Brokers Group, Inc. (IBKR) has not yet reached, with its 2026 intraday high sitting just below at approximately $96.82.
  • Strongest bullish factors: Industry-leading gross margins near 91%, a capital-light automated brokerage model, double-digit revenue growth, and a debt-free balance sheet that gives management substantial financial flexibility.
  • Key risks: Softer retail trading activity, compressed net interest margins in a shifting rate environment, and elevated valuation multiples that leave limited room for execution missteps.
  • Support and resistance: Near-term support sits in the $82–$85 zone, where multiple analyst price targets cluster; $100 represents both a psychological resistance level and the next major upside milestone.
  • Bottom line: Reaching $100 appears achievable if IBKR sustains its growth trajectory, but the move will likely require a catalyst — whether stronger-than-expected earnings, an uptick in trading volumes, or broader market tailwinds.

Why the $100 Level Matters

The $100 mark carries outsized significance for any stock, and Interactive Brokers is no exception. Round-number levels often act as psychological barriers where supply and demand dynamics shift, drawing attention from institutional traders, algorithmic strategies, and retail investors alike. For IBKR, which has rallied sharply from its 2025 lows near $36 to flirt with the high $90s in 2026, crossing into triple-digit territory would signal a major vote of confidence from the market.

Investors searching for "can IBKR reach $100" are effectively asking whether the company's remarkable run has enough fuel left to clear this widely watched threshold — and whether the fundamentals justify the price.

Company Overview

Interactive Brokers Group, Inc. operates one of the world's largest automated electronic brokerage platforms, serving individual investors, hedge funds, proprietary trading groups, financial advisors, and introducing brokers across more than 200 countries. The company's proprietary technology stack enables trade execution, clearing, settlement, and custody across stocks, options, futures, forex, bonds, precious metals, and cryptocurrencies. Founded in 1977 and headquartered in Greenwich, Connecticut, IBKR has built a reputation for low-cost execution and advanced trading tools that attract both sophisticated professional traders and a growing base of self-directed retail investors.

Current Market Position

IBKR shares have delivered extraordinary returns, gaining roughly 46% in 2025 and continuing that momentum into 2026. The stock reached an intraday high near $96.82 during the year, placing $100 squarely on the radar. The company generated approximately $6.21 billion in annual revenue for 2025, reflecting nearly 20% year-over-year growth. Client accounts and customer equity have expanded steadily, supported by IBKR's global reach and its ability to attract assets across market cycles.

What distinguishes IBKR from many peers is its structurally advantaged business model. The firm's automated platform produces gross margins around 91% — an exceptionally high figure in the financial services industry — while carrying zero long-term debt. This combination of profitability and balance-sheet strength provides a durable foundation for continued growth. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Could Drive the Next Leg Higher

Several catalysts could propel IBKR past $100. First, the company's international expansion remains underappreciated. IBKR continues to penetrate markets in Europe, Asia, and Latin America, where the addressable population of traders and investors is substantially larger than its current client base. Second, rising interest rates or sustained elevated rates boost net interest income on client cash balances — a meaningful revenue stream that directly benefits the bottom line.

Third, any resurgence in retail trading activity — whether driven by market volatility, new asset classes such as cryptocurrency, or product innovation like fractional share trading and overnight trading hours — could lift transaction-based revenue. Finally, IBKR's growing prime brokerage and custody business for hedge funds and registered investment advisors represents a high-margin growth avenue that analysts at firms including Redburn-Atlantic have highlighted as underappreciated.

What Could Prevent the Move

The path to $100 is not without obstacles. Trading volumes across the brokerage industry have softened at times, and a prolonged period of low market volatility could suppress commission revenue. Net interest margins, while benefiting from higher rates, could compress if central banks pivot toward rate cuts.

Valuation also warrants attention. At approximately 27 times forward earnings — or around 24 times normalized 2026 EPS estimates — IBKR is not cheap in absolute terms, even if bullish analysts argue the multiple is justified by the company's growth rate and margin profile. Any earnings miss or downward revision to guidance could trigger a swift repricing, particularly given the stock's strong run-up. Lastly, competitive pressure from both traditional brokers and newer fintech platforms such as HOOD (Robinhood) means IBKR must continuously invest in its platform to maintain its edge.

Analyst Opinions and Price Targets

Wall Street sentiment on IBKR remains broadly positive, with the consensus rating hovering in "Strong Buy" territory. Barclays and BMO Capital have maintained Overweight and Outperform ratings respectively, with recent price targets in the $82–$84 range as of early 2026. However, these targets have already been exceeded by the stock's market price, suggesting analysts may need to revise their models upward.

The most bullish voice comes from Redburn-Atlantic, which raised its price target to $246, citing IBKR's structurally advantaged model, global growth runway, and earnings power that the firm believes is above consensus. While the $246 target is an outlier, it underscores that some institutional analysts see significant untapped value. A more measured forecast from independent research firm 24/7 Wall St places a 12-month target at approximately $108, with an optimistic scenario reaching nearly $126 — both comfortably above the $100 threshold.

Technical Levels That Matter

From a technical perspective, $100 represents clear psychological resistance. The stock's 2026 high near $96.82 means that a breakout above $100 would also represent a new all-time high, potentially triggering momentum-driven buying. On the downside, the $82–$85 zone — where multiple analyst price targets have clustered — should provide meaningful support during any pullback. A deeper correction could test the $70–$75 area, which aligns with the stock's average trading range earlier in the year.

The broader trend structure remains intact, with IBKR consistently forming higher lows and higher highs since its 2022 trough. As long as that sequence continues, the path toward $100 remains technically viable. From what I see, the uptrend shows no immediate signs of breaking.

AI Daily Buy/Sell Signals

Traders monitoring IBKR's progress toward $100 can benefit from tools that simplify timely decision-making. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical patterns, and AI-driven analysis. I have found these signals helpful when cross-checking my own views on momentum and entry points. Rather than manually tracking every chart and indicator, traders can use these signals to identify emerging opportunities, monitor existing positions, and stay ahead of changing trends more efficiently. Exploring how AI-driven signals align with your own research can add a valuable layer of confirmation to your trading process.

Final Assessment

The question of whether Interactive Brokers can reach $100 appears more a matter of timing than impossibility. The company's structural advantages — an industry-leading automated platform, fortress-like balance sheet, global growth runway, and expanding product ecosystem — provide a solid foundation for further appreciation. Analyst sentiment remains overwhelmingly positive, and the technical uptrend shows no signs of exhaustion.

That said, the final push from the mid-$90s to $100 will likely require a specific catalyst: an earnings beat, a surge in trading activity, favorable interest-rate developments, or broader market strength. Investors should watch client account growth, trading volumes, and net interest margin trends as leading indicators. While no outcome is guaranteed, the evidence suggests that $100 is a realistic, near-term target that IBKR has the fundamental momentum to achieve — provided the market environment remains supportive.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IBKR

Contributor

<p>Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years&nbsp;developing&nbsp;his proprietary trading and quantitative algorithms (now Tickeron&rsquo;s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional,&nbsp;sophisticated stock market analysis capabilities to retail investors via&nbsp;an easy-to-use interface.</p>


IBKR in downward trend: price dove below 50-day moving average on July 31, 2026

IBKR moved below its 50-day moving average on July 31, 2026 date and that indicates a change from an upward trend to a downward trend. In of 28 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBKR as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for IBKR turned negative on July 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 10-day moving average for IBKR crossed bearishly below the 50-day moving average on August 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBKR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBKR advanced for three days, in of 331 cases, the price rose further within the following month. The odds of a continued upward trend are .

IBKR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 367 cases where IBKR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IBKR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.562) is normal, around the industry mean (4.148). P/E Ratio (34.123) is within average values for comparable stocks, (20.994). Projected Growth (PEG Ratio) (1.653) is also within normal values, averaging (1.663). Dividend Yield (0.004) settles around the average of (0.033) among similar stocks. P/S Ratio (3.467) is also within normal values, averaging (31.056).

Notable companies

The most notable companies in this group are Morgan Stanley (NYSE:MS), Goldman Sachs Group (NYSE:GS), Charles Schwab Corp (The) (NYSE:SCHW), Gold.com Inc. (NYSE:GOLD).

Industry description

These banks specialize in underwriting (helping companies with debt financing or equity issuances), IPOs, facilitating mergers and other corporate reorganizations and acting as a broker or financial advisor for institutions. They might also trade securities on their own accounts. Investment banks potentially thrive on expanding its network of clients, since that could help them increase profits. Goldman Sachs, Morgan Stanley and CME Group Inc are some of the largest investment banking companies.

Market Cap

The average market capitalization across the Investment Banks/Brokers Industry is 13.14B. The market cap for tickers in the group ranges from 13 to 928.5B. PKRSF holds the highest valuation in this group at 928.5B. The lowest valued company is BFCH at 13.

High and low price notable news

The average weekly price growth across all stocks in the Investment Banks/Brokers Industry was -1%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -14%. USDE experienced the highest price growth at 36%, while TOP experienced the biggest fall at -80%.

Volume

The average weekly volume growth across all stocks in the Investment Banks/Brokers Industry was -38%. For the same stocks of the Industry, the average monthly volume growth was -25% and the average quarterly volume growth was -69%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 70
Price Growth Rating: 63
SMR Rating: 76
Profit Risk Rating: 86
Seasonality Score: -7 (-100 ... +100)
View a ticker or compare two or three
IBKR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a holding company through its subsidiaries provides brokerage and investment services

Industry InvestmentBanksBrokers

Profile
Details
Industry
Investment Banks Or Brokers
Address
One Pickwick Plaza
Phone
+1 203 618-5800
Employees
3182
Web
https://www.interactivebrokers.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Interactive Brokers (IBKR): Can It Hit $100 After +46% Gains?